A phase II trial of murine monoclonal antibody 17-1A and interferon-γ: Clinical and immunological data
- 25 Downloads
A group of 15 patients with metastatic colorectal adenocarcinoma received a combination of interferon γ (0.1 mg/m2, days 1–15) and the murine monoclonal antibody 17-1A (400 mg, days 5, 7, 9 and 12). The treatment was tolerated with minimal toxicity. Of the 14 evaluable patients, 13 developed human antibody to murine 17-1A, with 11 patients demonstrating antibody to the variable region of 17-1A (anti-idiotype). Antibody to the variable region was inhibited by 17-1A but not by mouse immunoglobulin. Sera from patients with substantial anti-idiotype reactivity were capable of inhibiting the binding of murine 17-1A to antigen expressing LS174-T cells thus indicating the presence of antibody directed against the 17-1A combining site (mirror-image anti-idiotype). The median survival of the whole group was 56 weeks and there was no correlation between clinical response/survival and the development of anti-idiotype antibody.
KeywordsMonoclonal Antibody Adenocarcinoma Cancer Research Interferon Median Survival
Unable to display preview. Download preview PDF.
- 1.Balch CM, Tilden AB, Dougherty PA, Cloud GA, Abo T (1984) Heterogeneity of natural killer lymphocyte abnormalities in colon cancer patients. Surgery USA 95: 63Google Scholar
- 5.Hale G, Clark MR, Marcus R, Winter G, Dyer MJS, Phillips JM, Riechmann L, Waldmann H (1988) Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody compath-1H. Lancet, 1394Google Scholar
- 7.Jain RK (1987) Transport of molecules in the tumor interstitium: a review. Cancer Rep 47: 3039Google Scholar
- 12.Laszlo J, Huang AT, Brenckman WD, Jeffs C, Koren H, Cianciolo G, Metzgar R, Cashdollar W, Cox E, Buckley CE III, Tso CY, Lucas VS Jr (1983) Phase I study of pharmacological and immunological effects of human lymphoblastoid interferon given to patients with cancer. Cancer Res 43: 4458PubMedGoogle Scholar
- 14.LoBuglio AF, Khazaeli MB, Lee J, Haynes A, Sumerel L, Mischak R, Spitler L (1988) Pharmacokinetics and immune response to xomazyme-mel in melanoma patients. Antibody Immunoconjugate Radiopharmacol 1: 305Google Scholar
- 23.Schroff RW, Stevenson HC (1985) Human immune responses to murine monoclonal antibodies. In: Foon KA, Morgan AC (eds) Monoclonal antibody therapy of human cancer. Nijhoff, The Hague, p 121Google Scholar
- 24.Sears HG, Herlyn D, Steplewski Z, Koprowski H (1984) Effects of monoclonal antibody immunotherapy in patients with gastrointestinal adenocarcinoma. J Biol Response Modif 3: 138Google Scholar
- 30.Vadhan-Ray S, Cordon-Cardo C, Carswell E, Mintzer D, Dantis L, Duteau C, Templeton MA, Oettgen HF, Old LJ, Houghton AN (1988) Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol 6: 1636PubMedGoogle Scholar